donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 09969 INNOCARE-B > Key Indicators
09969 INNOCARE-B
11.460
-0.020-0.17%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Per Share IndicaTor
Operating Cash Flow Per Share
185.69% 0.1362 -84.3% -0.1411 -78.82% -0.159 -- -0.0765
Cash Flow Per Share
-9.35% 0.8008 -358.97% -0.6268 139.63% 0.8834 -- 0.242
Operating Income Per Share
67574.54% 0.8507 12729.29% 0.0815 -9.57% 0.0013 -- 0.0006
Net Asset Per Share
59.78% 4.5709 52.55% 4.369 185.4% 2.8608 -- 2.864
Basic Earning Per Share
89.28% -0.0612 66.86% -0.1923 94.52% -0.5703 -- -0.5802
Diluted  Earning Per Share
89.28% -0.0612 66.86% -0.1923 94.52% -0.5703 -- -0.5802
Profitability
Gross Profit Ratio
-6.3% 93.704% -9.66% 90.336% 0% 100.000% 0% 100.000%
Operating Profit Ratio
99.99% -1.618% 99.54% -208.872% 86.33% -23573.680% 17% -45047.995%
Net Profit Ratio
99.98% -6.393% 99.54% -209.607% 83.34% -28729.106% 16.88% -45112.834%
Earning Before Tax Ratio
99.99% -1.929% 99.53% -209.904% 83.34% -28729.106% 16.88% -45112.834%
ROE
99.46% -1.498% 97.73% -4.916% -- -278.668% -- -216.940%
ROA
90.23% -1.093% 59.25% -3.652% 87.27% -11.190% 33.78% -8.961%
Yield Quality
Operating Cash To Total Revenue
100.13% 16.017% 98.56% -173.160% -97.76% -12648.016% -116.89% -12049.859%
Capital Structure
Debt Assets Ratio
-22.56% 23.503% -26.2% 21.163% -85.73% 30.350% -80.17% 28.674%
Equity Multipler
-9.71% 1.3199 -10.1% 1.2807 -- 1.4619 -- 1.4246
Debt Equity Ratio
-29.49% 30.723% -33.23% 26.844% -- 43.575% -- 40.202%
Current Assets To tatal Assets
-3.81% 86.747% -2.11% 91.717% -2.07% 90.183% -0.72% 93.693%
Non Current Assets To Total Assets
35% 13.253% 31.33% 8.283% 24.08% 9.817% 12.09% 6.307%
Current Liabilities To tatal Liabilities
149.73% 18.941% 102.12% 9.711% 542.52% 7.584% 745.1% 4.805%
Non Current Liabilities To Total Liabilities
-12.29% 81.059% -5.15% 90.289% -6.48% 92.416% -4.26% 95.195%
Solvency
Current Ratio
-50.26% 19.487 -34.38% 44.6271 6.81% 39.1777 -40.75% 68.0062
Quick Ratio
-50.31% 19.4569 -- 44.5801 -- 39.1598 -- --
Operating Profit To Current Liabilities
98.34% -0.0512 70.93% -1.4797 90.6% -3.0784 67.05% -5.0906
Operrating Cash Flow To Current Liabilities
130.72% 0.5073 9.91% -1.2267 -36% -1.6516 13.89% -1.3617
Share Equity Without Minority Interest To Total Liabilities
43.03% 3.2236 50.71% 3.6895 517.32% 2.2539 850.22% 2.448
Operating Cash Flow To Total Liabilities
176.71% 0.0961 -82.08% -0.1191 -773.86% -0.1253 -627.66% -0.0654
Operating Profit To Total Liabilities
95.84% -0.0097 41.25% -0.1437 39.59% -0.2335 -178.46% -0.2446
Operating Capacity
Inventory Turnover(T)
-- 11.1846 -- 2.2855 -- -- -- --
Current Assets Turnover(T)
46689.98% 0.2007 8949.3% 0.0195 -22.14% 0.0004 -18.87% 0.0002
Fixed Assets Turnover(T)
36882.98% 2.8666 4108.81% 0.2994 -83.37% 0.0078 -92.82% 0.0071
Total Assets Turnover(T)
45207.95% 0.1767 8764% 0.0177 -23.83% 0.0004 -20% 0.0002
Growth Ability
Operating Revenue GR 3Y
5520.44% 69027.427% -- 18163.003% -- 1228.151% -- --
Operating Profit GR 3Y
1375.33% 96.736% -- 22.987% -- 6.557% -- --
EBT GR 3Y
791.98% 96.108% -- 22.607% -- -13.889% -- --
Net Profit GR 3Y
727.13% 87.102% -- 22.717% -- -13.889% -- --
Net Profit Attributable To The Parent Company GR 3Y
735.69% 87.422% -- 24.045% -- -13.752% -- --
Total Assets GR 3Y
-93.64% 259.319% -- -- -- 4078.180% -- --
Share Equity Without Minority Interest GR 3Y
-13.63% 762.633% -- -- -- 882.934% -- --
Equity GR 3Y
-8.42% 821.673% -- -- -- 897.184% -- --
Total Liabilities GR 3Y
-122.49% -38.844% -- -- -- 172.679% -- --
Other Indicators
Currency Unit
HKDHKDHKDHKD

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Nuocheng Jianhua Pharmaceutical Co., Ltd. is an investment holding company mainly engaged in biomedical business. The company discovers, develops and commercializes potentially best-in-class and pioneered drugs for the treatment of cancer and autoimmune diseases. The company has established an integrated biomedical platform with internal research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, as well as commercial production and sales.
CEO: Jisong Cui
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...